In order to accelerate the development of its therapies and their availability to patients, Genethon regularly forms partnerships with pharmaceutical laboratories and biotechs who can provide additional expertise and necessary resources.

Our partnership strategy

A laboratory created by a patient association, Genethon is particularly concerned with ensuring that the treatments derived from its research are accessible to those that need them. This is why we strive to work with partners that share our values. Find out more about our commitment.

To accelerate the development of its programs, Genethon employs a 3-pronged partnership strategy, with one goal, namely to innovate and work with other world leaders in gene therapy in order to make treatments avaialable to patients as quickly as possible.

  • Collaboration in order to develop new technologies and treatment strategies: capsids, vectors, immuno-modulation approaches, bioproduction systems.
  • Creation of a spin-off for specific projects, which represents an opportunity to partner or to invest for future partners.
    • The spin-off Atamyo was created in 2020. Its purpose is to develop gene therapy treatments for neuromuscular indications.

For any questions about our programs or our partnership strategy,
contact us!

Our industrial partners

Sarepta – DMD
Collaboration with license option – June 2017
License agreement and joint development – January 2020

Avexis – Spinal muscular atrophy
License agreement
March 2018

Audentes – Myotubular myopathy
Collaboration and license agreement
February 2014

Spark Therapeutics – Pompe Disease
Collaboration and license agreement
September 2017

GenSight biologics -Leber Hereditary Optic Neuropathy
Collaboration et license agreement

Whitelab Genomics – IA
Research collaboration
February 2021

Licencing agreement
March 2019

Samabriva – AAV
Research collaboration
June 2018

Research Collaboration with licencing option
September 2021